Skip to main content

Table 1 Baseline demographic and disease characteristics

From: Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

  Patients at Low Risk for TLS
n = 6
Patients at Increased Risk for TLS
n = 15a
All Patients
N = 21
Median age, years (range) 62 (54–67) 70 (53–84) 68 (53–84)
Age category, years, n (%)
 < 60 2 (33) 1 (7) 3 (14)
 60–69 4 (67) 5 (33) 9 (43)
 ≥ 70 0 9 (60) 9 (43)
Male, n (%) 4 (67) 9 (60) 13 (62)
Median longest diameter of largest lesion, cm (range) 3 (2–5) 8 (2–15) 4 (2–15)
Median circulating lymphocytes, 109/L (range) 1.7 (0.1–3.8) 1.1 (0.4–83.9) 1.2 (0.1–83.9)
Median creatinine clearance, mL/min (range) 108 (72–140) 57 (36–94) 70 (36–140)
Median number of prior therapies, n (range) 2 (1–2) 2 (1–4) 2 (1–4)
  1. TLS tumor lysis syndrome
  2. aNine (60%) patients had ≥ 1 lesion > 10 cm and 9 (60%) patients had baseline creatinine clearance < 60 mL/min